Jane Street Group LLC Cuts Holdings in Astria Therapeutics, Inc. (NASDAQ:ATXS)

Jane Street Group LLC lessened its stake in Astria Therapeutics, Inc. (NASDAQ:ATXS) by 67.3% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 36,736 shares of the biotechnology company’s stock after selling 75,644 shares during the period. Jane Street Group LLC’s holdings in Astria Therapeutics were worth $404,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. FMR LLC increased its holdings in Astria Therapeutics by 29.2% in the 3rd quarter. FMR LLC now owns 7,822,275 shares of the biotechnology company’s stock worth $86,123,000 after acquiring an additional 1,767,714 shares in the last quarter. Vestal Point Capital LP lifted its position in shares of Astria Therapeutics by 23.1% in the third quarter. Vestal Point Capital LP now owns 4,000,000 shares of the biotechnology company’s stock worth $44,040,000 after buying an additional 750,000 shares in the last quarter. Nantahala Capital Management LLC purchased a new position in Astria Therapeutics during the 2nd quarter valued at approximately $6,142,000. Redmile Group LLC purchased a new position in Astria Therapeutics during the 3rd quarter valued at approximately $3,423,000. Finally, Cubist Systematic Strategies LLC bought a new stake in Astria Therapeutics in the 2nd quarter worth approximately $2,561,000. 98.98% of the stock is owned by hedge funds and other institutional investors.

Astria Therapeutics Stock Performance

NASDAQ ATXS opened at $8.67 on Wednesday. Astria Therapeutics, Inc. has a fifty-two week low of $6.91 and a fifty-two week high of $16.90. The business’s 50 day moving average price is $10.06 and its 200-day moving average price is $10.72. The company has a market cap of $489.28 million, a P/E ratio of -4.15 and a beta of 0.70.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on ATXS shares. Oppenheimer raised their target price on shares of Astria Therapeutics from $26.00 to $28.00 and gave the company an “outperform” rating in a report on Thursday, November 14th. HC Wainwright reiterated a “buy” rating and set a $16.00 price objective on shares of Astria Therapeutics in a research report on Tuesday, December 10th. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $25.60.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.